[Federal Register Volume 88, Number 124 (Thursday, June 29, 2023)]
[Notices]
[Page 42090]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-13792]



[[Page 42090]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; Michael Shmilovich; [email protected]; telephone: 301-
435-5019. A signed Confidential Disclosure Agreement may be required to 
receive any unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Cannabinoid Receptor Modulating Compounds

    Available for licensing and commercial development are potentially 
therapeutic compounds for metabolic, inflammatory and fibrotic 
disorders. The filed patent applications includes extensive 
descriptions of the exemplary molecules and their various constituents. 
The cannabinoid receptor mediating compounds can be neutral 
antagonists. A CB1 inverse agonist is a drug that on its own 
produces an effect opposite to that of a CB1 agonist, and is 
also able to block the effect of a CB1 agonist. In contrast, 
a CB1 neutral antagonist can only do the latter (i.e., 
blocking the effect of a CB1 agonist), but has no effect on 
its own. CB1 inverse agonism is usually documented by the 
ability of a drug to decrease GTP[gamma]S binding and/or to increase 
adenylate cyclase activity. The compounds may show functional bias for 
GTP[gamma]S or [beta]-Arrestin or activity for both GTP[gamma]S and 
[beta]-Arrestin. Secondary targets could include, but not limited to, 
the enzyme inducible nitric oxide synthase (iNOS) or adenosine 
monophosphate kinase (AMPK), as suggested by findings that inhibition 
of iNOS or activation of AMPK improves insulin resistance, and reduces 
fibrosis and inflammation. The rights pursued claim compounds, 
pharmaceutical compositions, and methods of use.

Potential Commercial Applications

 Pharmaceuticals
 Cancer therapy
 Anti-fibrotic therapy
 Inflammatory and autoimmune disease

Development Stage

 Early stage

    Inventors: Malliga R. Iyer, Ph.D.; Pinaki Bhattacharjee, Ph.D.; 
Resat Cinar, PharmD, MBA; George Kunos, M.D., Ph.D.; Szabolcs Dvoracsko 
Ph.D., (all of NIAAA).
    Intellectual Property: HHS Reference No. E-189-2021-0; U.S. 
Provisional Patent Application No. 63/319,642 filed March 14, 2022; 
International Patent Application PCT/U2023/014846 filed March 8, 2023.
    Licensing Contact: Michael Shmilovich; 301-435-5019; 
[email protected].
    This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 
to achieve expeditious commercialization of results of federally-funded 
research and development.

    Dated: June 23, 2023.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2023-13792 Filed 6-28-23; 8:45 am]
BILLING CODE 4140-01-P